Skip to content

Independent register of U.S. FDA drug recalls · updated Oct 10, 2026

FDA drug recalls in 2015

Every FDA drug recall initiated in 2015, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

1,733 recalls, newest first.

Jun 2, 2015 Class II · Moderate risk

Testosterone USP

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1650-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone Propionate 100 mg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1649-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone USP Aqueous 200 mg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1648-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone Enanthate 200 mg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1647-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone Cypionate 200 mg/ml Anastrazole 0.25 mg/ml Cholecalciferol 50

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1646-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone Cypionate 200 mg/ml Anastrazole 2 mg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1645-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone Cypionate 200 mg/ml Anastrazole 0.5 mg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1644-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone Cypionate 200 mg/ml Anastrazole 0.25 mg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1643-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone Cypionate 200mg/ml Injection Multi-Dose Vial

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1642-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone Cypionate 150 mg/ml Injection Multi-Dose Vial

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1641-2015

Jun 2, 2015 Class II · Moderate risk

Testosterone Cypionate 100 mg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1640-2015

Jun 2, 2015 Class II · Moderate risk

SUPER LIPO Injectable

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1639-2015

Jun 2, 2015 Class II · Moderate risk

Sufentanil 50 mcg/ml + Bupivacaine 0.25 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1638-2015

Jun 2, 2015 Class II · Moderate risk

Sufentanil 50 mcg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1637-2015

Jun 2, 2015 Class II · Moderate risk

Sufentanil 45 mcg/ml + Bupivacaine 5 mg/ml Solution

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1636-2015

Jun 2, 2015 Class II · Moderate risk

Sodium Tetradecyl Sulfate 5% Injectable

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1635-2015

Jun 2, 2015 Class II · Moderate risk

Sodium Ascorbate 500 mg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1634-2015

Jun 2, 2015 Class II · Moderate risk

Sermorelin 300 mcg/ml + GHRP-2 300 mcg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1633-2015

Jun 2, 2015 Class II · Moderate risk

Sermorelin 1000mcg/GHRP6 1000/GHRP2 1000 ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1632-2015

Jun 2, 2015 Class II · Moderate risk

Sermorelin/GHRP6 1000/1000 mcg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1631-2015

Jun 2, 2015 Class II · Moderate risk

Sermorelin/GHRP2 1000/1000 mcg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1630-2015

Jun 2, 2015 Class II · Moderate risk

Sermorelin 1000 mcg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1629-2015

Jun 2, 2015 Class II · Moderate risk

Selenium 200 mcg/ml Injectable

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1628-2015

Jun 2, 2015 Class II · Moderate risk

Pyridoxine Hydrochloride 100 mg/ml Injectable

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1627-2015

Jun 2, 2015 Class II · Moderate risk

Progesterone 100 mg/ml Injection

Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

Terminated Sterility / contamination The Compounding Pharmacy of America D-1626-2015

Recalls by year

2026563
2025778
2024557
20231,122
20221,390
20211,152
2020930
20191,788
20181,681
20171,141
20161,199
20151,733
20141,309
20132,085
2012534
201134
20104
20072
20061